Delivery Order SPE2DR25D2003-SPE2DR26FQ95X
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside order carries a ceiling value of $11,698.84 with firm fixed pricing and is scheduled for completion by September 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor supporting federal medical procurement...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a firm fixed-price delivery order valued at $100,610.15 by the Defense Logistics Agency (DLA) for the supply of Xeljanz 5 mg tablets in quantities of 60 units. The award, issued on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a competitive procurement with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) valued at $8,107.66 under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical supplies to federal healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $5,034.64 to supply Xeljanz XR 11 mg tablets (30-count units) with a completion date of October 24, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a single delivery order under a larger contract vehicle. The pharmaceutical will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $20,512.96 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a $51,681.43 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procurement procedures. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $36,947 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30-count units. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of October 28, 2025, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a single-transaction purchase under the company's existing federal pharmaceutical supply agreements. AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30-tablet units, with a contract ceiling value of $13,740.06. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for ultimate completion on September 12, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Xeljanz XR 11 mg tablets in 30-unit packages, with a contract ceiling value of $1,685.35. This firm fixed price delivery order, set to conclude by November 17, 2025, represents a competitive award under AmerisourceBergen's broader indefinite delivery contract with the DLA. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $68,386.11, was competitively awarded with no set-aside designation and is scheduled for completion by September 25, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DR25D2003Indefinite Delivery Contract
- SPE2DR25D2003-SPE2DR26FQ95XDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Xeljanz XR 11 mg tablets in 30-unit packages. The contract, valued at $11,000.28, is a firm fixed-price delivery order with an ultimate completion date of November 13, 2025, and was competitively awarded without set-aside provisions. Performance will take place at the vendor's corporate office location in Conshohocken, PA. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen's federal contract portfolio demonstrates significant capability in supplying critical pharmaceuticals and medical supplies to Department of Defense and veteran healthcare systems. The company's IDC with DLA encompasses a broad range of therapeutic products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The current award for Xeljanz XR—a prescription medication used in rheumatologic and other immune-mediated conditions—reflects the vendor's ongoing role as a key pharmaceutical provider supporting military and federal healthcare procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.0k | 11/12/25 |